News
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...
Trump Cuts Tariff Rate to 15% on Japan - The U.S. and Japan struck a major trade deal overnight. Trump confirmed a 15% tariff ...
Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...
Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...
Barchart on MSN1d
S&P Futures Gain With Focus on U.S. JOLTs Report and Corporate Earnings, FOMC Meeting on Tap
September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning, extending yesterday’s gains, while investors ...
6don MSN
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. A visit to the chiropractor can provide many health benefits.
Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.
Investors braced for the Federal Reserve's next interest rate decision and earnings from tech giants Microsoft and Meta.
What's next for the stock market? Dow and Nasdaq futures rise as investors await Big Tech earnings and interest rate decision ...
FDA recommends lifting the hold on Sarepta's gene therapy Elevidys for ambulatory patients after investigation; ...
The Fed is expected to keep rates steady, but Powell will get questions on Fed independence. Apple, Microsoft, Meta and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback